NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Forecast & News

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its quarterly earnings results on Thursday, November, 21st. The biotechnology company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.56 by $0.12. The biotechnology company earned $51.30 million during the quarter, compared to analyst estimates of $55.95 million. Enanta Pharmaceuticals had a net margin of 22.60% and a return on equity of 10.46%. Enanta Pharmaceuticals's revenue for the quarter was down 23.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.30 EPS. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Enanta Pharmaceuticals.

4 Wall Street analysts have issued 12 month target prices for Enanta Pharmaceuticals' shares. Their forecasts range from $57.00 to $130.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $101.33 in the next twelve months. This suggests a possible upside of 74.9% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

News articles about ENTA stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a news sentiment score of -3.6 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Enanta Pharmaceuticals.

Enanta Pharmaceuticals saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 2,440,000 shares, an increase of 7.0% from the November 28th total of 2,280,000 shares. Based on an average daily trading volume, of 197,600 shares, the short-interest ratio is presently 12.3 days. Currently, 14.1% of the company's stock are sold short. View Enanta Pharmaceuticals' Current Options Chain.

Some companies that are related to Enanta Pharmaceuticals include BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), United Therapeutics (UTHR), Allakos (ALLK), SAGE Therapeutics (SAGE), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), FibroGen (FGEN), Mirati Therapeutics (MRTX), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC- (GWPH), Ultragenyx Pharmaceutical (RARE), Myokardia (MYOK) and Deciphera Pharmaceuticals (DCPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Pandora Media (P), Ryder System (R), Tandem Diabetes Care (TNDM), NVIDIA (NVDA), Ford Motor (F), Wells Fargo & Co (WFC), Alibaba Group (BABA) and Tesla (TSLA).

Enanta Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.06%), Wedge Capital Management L L P NC (0.03%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System and State of Alaska Department of Revenue. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Nathaniel S Gardiner, Paul J Mellett and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was purchased by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $57.94.

Enanta Pharmaceuticals has a market capitalization of $1.14 billion and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.View Additional Information About Enanta Pharmaceuticals.

The official website for Enanta Pharmaceuticals is http://www.enanta.com/.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]